Skip to main content

Table 3 Longitudinal change (week 0, 4, 8) in HBD1 in the treatment groups compared to Placebo (n = 18)

From: Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D3 as host directed therapy

 

Crude

Adjusteda

HBD1

β(95% CI)

p-value

β(95% CI)

p-value

PBA (n = 18)

0.26 (−0.10, 0.62)

0.15

0.31 (−0.06, 0.67)

0.10

vitD3 (n = 18)

−0.05 (− 0.40, 0.29)

0.76

0.04 (− 0.31, 0.40)

0.81

PBA + vitD3 (n = 18)

0.21 (−0.15, 0.56)

0.25

0.28 (−0.09, 0.66)

0.14

  1. Data is presented as beta coefficient with 95% confidence intervals in parentheses
  2. Abbreviations: CI confidence interval, HBD1 human beta-defenisn-1
  3. aAdjusted for age, sex, duration of treatment, history of contact with active TB cases, time and the interaction between the treatment groups and time.
  4. Statistical analysis was performed using generalized estimating equation (GEE) model. P-value of < 0.05 is significant
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us